Gore Range Capital

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

Bioquintex Laboratories specializes in developing innovative blood collection and analysis solutions. Founded in 2010 and located in Lee's Summit, Missouri, the company provides micro and dried blood collection tools designed to simplify blood testing. Their services cater to various sectors, including corporate wellness, epidemiological research, pharmaceuticals, clinical trials monitoring, and insurance underwriting. Bioquintex operates a laboratory that is both CAP accredited and CLIA certified, ensuring high-quality sample testing. The company's platform offers convenient options for biometric screenings, including venipuncture and fingerstick methods, streamlining specimen analysis and processing while reducing the need for traditional needle phlebotomy.

xMD Diagnostics operates in the healthcare industry focusing on biotechnology business. The company was formerly known as Bay Resources Development Group. The company is headquartered in Annapolis, Maryland. xMD Diagnostics uses high-throughput microdissection technology for the diagnosis of cancer.

BioXcel Therapeutics is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in drug development using artificial intelligence. The company focuses on neuroscience and immuno-oncology, aiming to identify new therapeutic options for conditions with significant unmet medical needs. Its pipeline includes BXCL501, a sublingual film formulation of dexmedetomidine, which is approved for the acute treatment of agitation related to schizophrenia and bipolar disorders. Additionally, BioXcel is developing BXCL701, an immuno-oncology agent targeting rare prostate and pancreatic cancers. The company collaborates with partners to enhance its research and development efforts in these therapeutic areas. Founded in 2017, BioXcel Therapeutics aims to innovate and streamline the drug development process through its AI-driven approach.

Eirion Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of advanced prescription products for aesthetic dermatology. The company's product pipeline includes treatments aimed at addressing various conditions such as wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion is committed to meeting significant unmet clinical needs within the field, with plans to explore additional indications in the future. Through its innovative approach, Eirion Therapeutics aims to provide effective solutions for both physicians and patients dealing with aesthetic concerns.

Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.

Medikly, Inc. provides a digital marketing platform for healthcare marketers. Its digital marketing platform enables marketers to capture and apply actionable physician intelligence. The company also provides MediklyOS, a solution that enables brands to launch, execute, modify, and measure marketing campaigns; and consulting, support, training, integration, and campaign services. Medikly, Inc. was founded in 2009 and is based in Jersey City, New Jersey.

Conversa Health, Inc. specializes in developing patient relationship management solutions that enhance communication between patients and healthcare providers. Its primary offering, the Conversa Virtual Care and Communication Platform, enables efficient engagement and improved health outcomes by automating personalized messaging tailored to individual patient profiles, which are derived from electronic health records, biometric devices, and self-reported data. The platform supports various healthcare scenarios, including chronic care management, acute discharge, and preventative wellness. Additionally, Conversa provides Digital Checkups that generate tailored clinical questions and reminders based on patient data. The company serves a diverse clientele, including health systems, pharmaceutical companies, payers, and health technology firms. Founded in 2013 and headquartered in Portland, Oregon, Conversa has expanded its presence with offices in New York, North Carolina, and California. Its solutions are utilized by notable organizations to manage patient engagement, especially during the COVID-19 pandemic, by facilitating symptom checks, lab result communications, and patient monitoring.

NovaScan, Inc. is a company dedicated to the development and manufacturing of innovative cancer detection devices. Founded by the former Dean of the Engineering School at the University of Wisconsin Milwaukee, NovaScan specializes in a non-invasive detection platform that utilizes Cole relaxation frequency technology for the identification and stratification of various cancers. Its product line includes MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, FastScan Probe for breast cancer identification, and additional technologies that facilitate electrical mammograms and the detection of multiple cancer types. The company, incorporated in 2001 and headquartered in Chicago, Illinois, focuses on improving patient outcomes and reducing healthcare costs through its rapid, accurate diagnostic solutions, which do not require extensive capital equipment or are limited by size. NovaScan's technologies are designed to enhance minimally invasive procedures and optimize therapeutic dosing within tumors, reflecting its commitment to advancing cancer care.

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.